Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 401–500 of 1,000
Chen, D., Wu, J., & Li, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055296 · Cited by 38
“However, dual RAAS blockade exerts side effects for DKD treatment indicating the harm of efferent arteriole (Parving et al., 2012; Fried et al., 2013).”
BackgroundDiabetes and cardiorenal syndrome: Understanding the “Triple Threat”
Banerjee, S. K., & Panas, R. M. (2017) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2017.01.003 · Cited by 31
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.07.004 · Cited by 34
Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure
Grosman‐Rimon, L., Billia, F., Wright, E., Carasso, S., Elbaz‐Greener, G., Kachel, E., Rao, V. A., & Cherney, D. Z. I. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09860-8 · Cited by 36
Gonzalez‐Calero, L., Martin‐Lorenzo, M., de la Cuesta, F., Maroto, A. S., Martin, M. B., Ruiz‐Hurtado, G., Pulido-Olmo, H., Segura, J., Barderas, M. G., Ruilope, L. M., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0331-7 · Cited by 32
“However, regression of albumin excretion in response to treatment does not necessarily imply improved CV prognosis [29–31].”
BackgroundSarafidis, P. A., Memmos, E., Alexandrou, M. E., & Papagianni, A. A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190306162658 · Cited by 31
Improvement of cardiovascular remodelling by chymase inhibitor
Takai, S., & Jin, D. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12549 · Cited by 32
“However, combination therapies with RASrelated agents have not demonstrated their utility because of their increased side effects in clinical studies.(75,76) Thus, combination therapies may cause a stronger systemic influence than individual therapies.”
BackgroundCapítulo 14 – Crise Hipertensiva
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160164 · Cited by 33
Motrapu, M., Świderska, M. K., Aranda, I. M., Marschner, J. A., Lei, Y., Valenzuela, L. M., Fu, J., Lee, K., Angelotti, M. L., Antonelli, G., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070703 · Cited by 30
Imai, E., Haneda, M., Yamasaki, T., Kobayashi, F., Harada, A., Ito, S., Chan, J. C. N., & Makino, H. (2013) · Hypertension Research · doi:10.1038/hr.2013.86 · Cited by 29
Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes
Humalda, J. K., Goldsmith, D. J. A., Thadhani, R., & de Borst, M. H. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu404 · Cited by 33
“Combination of a RAAS-blocking compound (ACEi or ARB) with the direct renin inhibitor aliskiren even increased the cardiorenal risk, along with a higher incidence of hyperkalemia and hypotension [12].”
BackgroundChoice of anti-hypertensive agents in diabetic subjects
Patel, B. M., & Mehta, A. A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113485250 · Cited by 33
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 43
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Chertow, G. M., & de Zeeuw, D. (2014) · PubMed · doi:10.1056/nejmc1400872 · Cited by 18
Tian, M., Shen, Y., Sun, Z.-L., & Zha, Y. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-0968-2 · Cited by 31
Teo, K. K., Pfeffer, M. A., Mancia, G., O'Donnell, M. J., Dagenais, G. R., Díaz, R., Dans, A., Liu, L., Bosch, J., Joseph, P. G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu079 · Cited by 28
“The APOLLO results on safety and tolerability appear to differ from those reported in the ALTITUDE trial which reported an excess of elevated serum potassium levels or renal dysfunction with aliskiren at similar doses.(18) However, patients in ALTITUDE all had diabetes and impaired renal function and all also received…”
ResultSelf-citationMallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 31
Transdermal contraception and the renin-angiotensin-aldosterone system in premenopausal women
Odutayo, A., Cherney, D. Z. I., Miller, J., Ahmed, S. B., LAI, V. S., Dunn, S., Pun, N., Moineddin, R., & Hladunewich, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00602.2014 · Cited by 30
Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling
Pan, J., Guleria, R. S., Zhu, S., & Baker, K. M. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3020566 · Cited by 31
“ARBs in diabetic hypertensive patients with chronic kidney disease is controversial [51,52].”
BackgroundRubattu, S. D., Cotugno, M., Forte, M., Stanzione, R., Bianchi, F., Madonna, M., Marchitti, S., & Volpe, M. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001762 · Cited by 28
Fahim, A. M. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108663 · Cited by 30
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Zain, M., & Awan, F. R. (2014) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps/27/5/2014/2428/1379-1391 · Cited by 33
Kristensen, S. L., Mogensen, U. M., Tarnesby, G., Gimpelewicz, C. R., Ali, M. A., Shao, Q., Chiang, Y., Jhund, P. S., Abraham, W. T., Dickstein, K., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.896 · Cited by 27
Self-citationRoy, A., Maiti, A., Sinha, A., Baidya, A., Basu, A. K., Sarkar, D., Sanyal, D., Biswas, D., Maisnam, I., Pandit, K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00921-y · Cited by 27
Riet, L. T., van den Heuvel, M., Peutz‐Kootstra, C. J., van Esch, J. H. M., van Veghel, R., Garrelds, I. M., Musterd‐Bhaggoe, U. M., Bouhuizen, A. M., Leijten, F. P. J., Danser, A. H. J., et al. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00010.2014 · Cited by 27
Nephrology research—the past, present and future
Floege, J., MAK, R. H. K., Molitoris, B. A., Remuzzi, G., & Ronco, P. M. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.152 · Cited by 29
Zhang, H., Yang, Y., Wang, Y., Wang, B., & Li, R. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s149298 · Cited by 29
“Although major advances in the diagnosis and treatment of DN have been made over the past few decades, it is still very difficult to significantly reduce mortality in this population.(7,8) The pathogenesis of DN remains unclear.”
The renin-angiotensin-aldosterone system: An old tree sprouts new shoots
Ruan, Y., Yu, Y., Wu, M., Jiang, Y., Qiu, Y., & Ruan, S. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111426 · Cited by 28
Sato, A. (2015) · Hypertension Research · doi:10.1038/hr.2015.19 · Cited by 26
Is it AKI or Nonrecovery of Renal Function That Is Important for Long-Term Outcomes?
Coca, S. G. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12621212 · Cited by 26
Brunström, M., Eliasson, M., Nilsson, P. M., & Carlberg, B. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001183 · Cited by 27
“The main difference between the analyses stratified by baseline and attained SBP is the inclusion of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) Trial in the baseline analyses [30].”
Manini, T. M., Anton, S. D., Beavers, D. P., Cauley, J. A., Espeland, M. A., Fielding, R. A., Kritchevsky, S. B., Leeuwenburgh, C., Lewis, K. H., Liu, C. K., et al. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14965 · Cited by 28
Antifibrotic Roles of RAAS Blockers: Update
Zhang, Y., Yu, Y., & Yu, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_33 · Cited by 30
Haruhara, K., Suzuki, T., Wakui, H., Azushima, K., Kurotaki, D., Kawase, W., Uneda, K., Kobayashi, R., Ohki, K., Kinguchi, S., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.031 · Cited by 28
Cavero‐Redondo, I., Saz‐Lara, A., Lugones‐Sánchez, C., Pozuelo‐Carrascosa, D. P., Gómez‐Sánchez, L., López‐Gil, J. F., García‐Ortiz, L., Bruno, R. M., & Gómez-Marcos, M. Á. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1225795 · Cited by 28
Hypertension Guidelines: More Challenges Highlighted by Europe
Jennings, G., & Touyz, R. M. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02034 · Cited by 27
Ciuceis, C. D., Savoia, C., Arrabito, E., Porteri, E., Mazza, M., Rossini, C., Duse, S., Semeraro, F., Rosei, C. A., Alonzo, A., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03380 · Cited by 27
“However, recently, concerns have raised about the clinical use of aliskiren in patients with NIDDM, especially when associated with ACE inhibitors, by the results of at least a couple of studies,(44,45) suggesting that the addition of aliskiren to standard therapy with renin–angiotensin system blockers might be even h…”
ResultAn update of the blockade of the renin angiotensin aldosterone system in clinical practice
Márquez, D. F., Ruiz‐Hurtado, G., Ruilope, L. M., & Segura, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1079623 · Cited by 27
“Effects on secondary renal end points were similar [13].”
BackgroundMethodResultInfluentialVaduganathan, M., Cheema, B. S., Cleveland, E., Sankar, K. N., Subacius, H. P., Fonarow, G. C., Solomon, S. D., Lewis, E. F., Greene, S. J., Maggioni, A. P., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.973 · Cited by 27
Self-citationEffects of sodium glucose cotransporter type 2 inhibitors on heart failure
Nassif, M. E., & Kosiborod, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13678 · Cited by 28
“Recent data suggest that even when all traditional risk factors for ASCVD are well controlled, patients with T2D continue to have a substantially greater risk of developing HF—indicating that traditional risk factor control is insufficient from a HF prevention standpoint, and highlighting the need for novel, more effe…”
BackgroundInfluentialNaha, S., Gardner, M., Khangura, D., Kurukulasuriya, L. R., & Sowers, J. R. (2014) · Cited by 27
Pratley, R. E., Husain, M., Lingvay, I., Pieber, T. R., Mark, T., Saevereid, H. A., Møller, D. V., Zinman, B., & the DEVOTE Study Group (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0960-8 · Cited by 25
Zhou, D., Zhou, T., Tang, S., Li, Q., Li, W., Gan, G., Li, M., & Qiu, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1354950 · Cited by 34
“Combining the renin inhibitor aliskiren with an ACEI or ARB signi fi cantly increased the risk of hyperkalemia and did not reduce the risk of cardiovascular disease or renal failure (29).”
BackgroundDual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny
Gentile, G., Remuzzi, G., & Ruggenenti, P. L. (2014) · The Nephron journals/Nephron journals · doi:10.1159/000368331 · Cited by 25
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 28
The therapeutic effect of mesenchymal stem cells in diabetic kidney disease
Habiba, U. E., Khan, N., Greene, D. L., Shamim, S., & Umer, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02432-w · Cited by 27
“However, it is important to note that the combination of an ACEI with an ARB is generally contraindicated as it has been shown to increase the risk of kidney injury and hyperkalemia [73–75].”
BackgroundYokokawa, F. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.791279 · Cited by 25
“Moreover, some questions about DRIs have arisen from the premature termination of the ALTITUDE clinical trial, which aimed to determine the effect of aliskiren as add-on to standard therapy with RAAS blockade (ACEIs or ARBs) in patients with type 2 diabetes who are at high risk for cardiovascular and renal events [87].”
BackgroundHave we reached the limits for the treatment of diabetic nephropathy?
Hajhosseiny, R., Khavandi, K., Jivraj, N. K., Mashayekhi, S., Goldsmith, D. J. A., & Malik, R. A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892580 · Cited by 29
“However, despite a minor additional reduction in blood pressure and reduction in albumin--creatinine ratio (ACR), there was a significant increase in hyperkalaemia and hypotension, leading to early termination of this trial [69].”
BackgroundKhan, U., Garg, A. X., Parikh, C. R., & Coca, S. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071784 · Cited by 28
“Recent, well designed trials to evaluate the effect of reduction of proteinuria did not show any significant improvement in hard outcomes [75,76].”
BackgroundNonsteroidal mineralocorticoid antagonists in diabetic kidney disease
Dojki, F. K., & Bakris, G. L. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000340 · Cited by 26
Should ACE inhibitors and ARBs be used in combination in children?
Stotter, B. R., & Ferguson, M. A. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4046-8 · Cited by 29
Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000426 · Cited by 24
Nardoianni, G., Pala, B., Scoccia, A., Volpe, M., Barbato, E., & Tocci, G. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00634-4 · Cited by 30
“Its administration is currently limited to those hypertensive patients without diabetes and renal impairment [65], or heart failure [66] and not assuming other RAS blocking agents.”
Simeoni, M., Nicotera, R., Colao, M., Citraro, M. L., Pelagi, E., Cerantonio, A., Comi, N., Coppolino, G., & Fuíano, G. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1128-4 · Cited by 24
“Even the add-on aliskiren in 45 Caucasian patients with CKD treated with dual blockade of RAAS showed a significant and persistent decrease in proteinuria with a not significant decrease in renal function [35].”
BackgroundThe New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
García-Carro, C., Vergara, A., Agraz, I., Jacobs-Cachá, C., Espinel, E., Serón, D., & Soler, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060864 · Cited by 29
Цукровий діабет і артеріальна гіпертензія
Сергієнко, В. О., & Serhiyenko, O. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.2.2021.230573 · Cited by 30
Kjeldsen, S. E., Aksnes, T. A., & Ruilope, L. M. (2014) · Drugs in R&D · doi:10.1007/s40268-014-0049-5 · Cited by 30
“Dual RAS blockade is no longer recommended owing to concerns regarding renal damage and an increased incidence of stroke [57, 58].”
BackgroundHypertension Management in Diabetic Kidney Disease
Patney, V., Whaley‐Connell, A. T., & Bakris, G. L. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.175 · Cited by 28
Rutkowski, B., & Tylicki, L. (2015) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2014.10.026 · Cited by 26
Novel avenues for treating diabetic nephropathy: new investigational drugs
Lacava, V., Pellicanò, V., Ferrajolo, C., Cernaro, V., Visconti, L., Conti, G., Buemi, M., & Santoro, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1293039 · Cited by 24
“For these reasons, the use of aliskiren with ACE inhibitors or ARBs is not recommended in DKD [50].”
BackgroundAntlanger, M., Bernhofer, S., Kovarik, J. J., Kopecky, C., Kaltenecker, C. C., Domenig, O., Poglitsch, M., & Säemann, M. D. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1313447 · Cited by 24
“Yet, several large-scale clinical trials showing non-superior or even inferior outcomes of the DRI aliskiren compared to other RAS blockers have led to a meanwhile infrequent use of this agent (12-17).”
BackgroundViazzi, F. C., Greco, E., Ceriello, A., Fioretto, P., Giorda, C. B., Guida, P., Russo, G. T., Cosmo, S. D., Pontremoli, R., & AMD-Annals Study Group (2018) · Kidney & Blood Pressure Research · doi:10.1159/000488255 · Cited by 26
Guo, F., Zhang, W., Su, J. Y., Xu, H., & Yang, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00049 · Cited by 28
“1409 disease genes related to hypertension were downloaded from DisGeNET Database via MeSH term D006973 (Piñero et al., 2017).”
MethodGeorgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 27
“…an additive albuminuria-lowering effect of combined treatment with an angiotensin-converting-enzyme inhibitor (ACEI) and an angiotensin-receptor blocker (ARB) [9], two large trials were designed to investigate the potential benefits of dual RAS-blockade on “hard” clinical outcomes [10, 11].”
Emerging therapies in immunoglobulin A nephropathy
Yeo, S. C., Liew, A., & Barratt, J. (2015) · Nephrology · doi:10.1111/nep.12527 · Cited by 24
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
Majewski, C., & Bakris, G. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0713-y · Cited by 23
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 25
“Kidney International Supplements (2022) 12, 27–35 need for well-designed, long-term phase III studies.(14,15) A summary of the characteristics and effects of steroidal MRAs in patients with CKD and T2D is provided in Table 1.”
BackgroundSzeto, C., Kwan, B. C., Chow, K., Leung, C., & Li, P. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062736 · Cited by 25
“9 months, and the reduction in urinary albumin-to-creatinine ratio was greater in the aliskiren group, the proportions of patients with hyperkalemia and hypotension were both significantly higher in the aliskiren than the placebo group [32].”
BackgroundReview of direct renin inhibition by aliskiren
Friedrich, S., & Schmieder, R. E. (2013) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313497328 · Cited by 29
Anguiano, L., Lei, Y., Devarapu, S. K., & Anders, H. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx219 · Cited by 26
Action plan for optimizing the design of clinical trials in chronic kidney disease
Perkovic, V., Craig, J. C., Chailimpamontree, W., Fox, C. S., García-García, G., Gharbi, M. B., Jardine, M., Okpechi, I. G., Pannu, N., Stengel, B., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.009 · Cited by 25
Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
Mancia, G., & Grassi, G. M. (2018) · Diabetologia · doi:10.1007/s00125-017-4537-3 · Cited by 26
I Brazilian Position Paper on Antihypertensive Drug Combination
Póvoa, R., Barroso, W. K. S., Brandão, A. A., Jardim, P. C. B. V., Barroso, O., Passarelli, O., Gemelli, J. R., Feitosa, A. D. M., Jardim, T. V., Carneiro, S. B., et al. (2014) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20140023 · Cited by 30
Lauder, L., Weber, T., Böhm, M., Brouwers, S., Bruno, R. M., Gerdts, E., Kreutz, R. H., Lüscher, T. F., Mancia, G., McEvoy, J. W., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01187-2 · Cited by 30
“Although BP reduction is a generally accepted surrogate for CVD outcomes, a few instances show that BP lowering might not necessarily translate into reductions in the risk of CVD, possibly because of known or unknown harmful offtarget effects that offset the overall benefit of treatment 72 .”
The renin–angiotensin system – a therapeutic target in COVID-19?
Sturrock, B. R., Milne, K. M., & Chevassut, T. J. T. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0146 · Cited by 23
Potential New Agents for the Management of Hyperkalemia
Packham, D., & Kosiborod, M. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0130-7 · Cited by 23
“A sub-analysis of ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) trial data indicated that dual RAAS blockade increases patients’ risk of hyperkalemia [54, 55], and recent trials of intensive dual or triple RAAS blockade were prematurely discontinued due to associated hyper…”
Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths
Dieter, B. P., Alicic, R. Z., Meek, R. L., Anderberg, R. J., Cooney, S. K., & Tuttle, K. R. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.167 · Cited by 22
Ramya, K., Suresh, R., Kumar, H. Y., Kumar, B. R. P., & Murthy, N. B. S. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115466 · Cited by 26
“63,73 The Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) trail investigations revealed that the addition of aliskiren to standard therapy with RAS blockades in patients with type 2 diabetes has no impact on cardiovascular and renal events, and it may be even detrimental.(74) The Aliskiren Tr…”
National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012
Zhou, M., Daubresse, M., Stafford, R. S., & Alexander, G. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119292 · Cited by 24
“Although results from three clinical trials and several observational studies supported Aliskiren’s effectiveness in reducing blood pressure [7,8,9,10,11,12], evidence also suggests Aliskiren is associated with higher rates of adverse events compared with placebo in diabetic patients concomitantly treated with ARBs or…”
BackgroundResultThe End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade?
de Zeeuw, D. (2013) · New England Journal of Medicine · doi:10.1056/nejme1312286 · Cited by 25
Xie, X.-X., Liu, P., Wan, F.-Y., Lin, S.-G., Zhong, W.-L., Yuan, Z.-K., Zou, J.-J., & Liu, L.-B. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.197 · Cited by 21
Zhao, B., Xu, Y., Chen, Y., Cai, Y., Gong, Z., Li, D., Kuang, H., Liu, X., Zhou, H., Liu, G., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.927078 · Cited by 25
“At present, RAAS inhibitors (ACEIs and ARBs) are recommended as the first-line medication in the clinical practice for hypertensive patients with renal disease, which can cause all kinds of adverse reactions such as excessive blood pressure reduction or elevated blood potassium levels (in the elderly patients), result…”
BackgroundSchroten, N. F., Damman, K., Hemmelder, M. H., Voors, A. A., Navis, G. J., Gaillard, S., van Veldhuisen, D. J., van Gilst, W. H., & Hillege, H. L. (2015) · American Heart Journal · doi:10.1016/j.ahj.2014.12.016 · Cited by 21
Capítulo 9 - Hipertensão Arterial na gestação
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Poli‐de‐Figueiredo, C. E., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160159 · Cited by 62
¿Cómo tratar la hipertensión arterial sistémica? Estrategias de tratamiento actuales
Gopar‐Nieto, R., Ezquerra-Osorio, A., Chávez-Gómez, N. L., Manzur‐Sandoval, D., & Raymundo-Martínez, G. I. (2021) · Archivos de cardiología de México · doi:10.24875/acm.200003011 · Cited by 52
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
“Renal Disease Endpoints (ALTITUDE) trials similarly assessed combination RAAS blockade but were discontinued early due to increased rates of hyperkalemia, AKI, and hypotension [88,89].”
BackgroundAn, J., Niu, F., & Sim, J. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2633 · Cited by 21
Sarafidis, P. A., Pella, E., Kanbay, M., & Papagianni, A. A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220825121304 · Cited by 24
Kôyama, A., Fujita, T., Gejyo, F., Origasa, H., Isono, M., Kurumatani, H., Okada, K., Kanoh, H., Kiriyama, T., & Yamada, S. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0130-5 · Cited by 22
“In addition, the use of combination therapy of renin-angiotensin system (RAS) inhibitors such as ACEI and ARB has demonstrated in some recent clinical trials to be not effective [6–9].”
MethodTherapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
Vivian, E., & Mannebach, C. (2013) · Drugs in Context · doi:10.7573/dic.212249 · Cited by 34
Afghahi, H., Svensson, M. K. E., Pirouzifard, M., Eliasson, B., & Svensson, A. (2015) · Diabetologia · doi:10.1007/s00125-015-3548-1 · Cited by 21
“The effects of BP lowering and/or RAAS blockade are therefore still under debate [27, 28].”
BackgroundPetrák, O., Zelinka, T., Štrauch, B., Rosa, J., Šomlóová, Z., Indra, T., Turková, H., Holaj, R., & Widimsky, J., Jr. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2015.24 · Cited by 23
Smink, P. A., Hoekman, J., Grobbee, D. E., Eijkemans, M. J. C., Parving, H.-H., Persson, F., Ibsen, H., Lindholm, L. H., Wachtell, K., de Zeeuw, D., et al. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313481754 · Cited by 24
“In all scenarios the albuminuria reduction was insufficient to overcome the harmful effect of changes in other off-target risk markers.(14) We here provide the first prospective drug efficacy estimation with the PRE score.”
BackgroundSelf-citationSeferović, J. P., Pfeffer, M. A., Claggett, B. L., Desai, A. S., de Zeeuw, D., Haffner, S. M., McMurray, J. J. V., Parving, H., Solomon, S. D., & Chaturvedi, N. (2017) · Diabetologia · doi:10.1007/s00125-017-4485-y · Cited by 23
“The trial design and results have been published previously [12, 13].”
ResultSelf-citationAmelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor β2 Agonist
Trasino, S. E., Tang, X., Shevchuk, M. M., Choi, M. E., & Gudas, L. J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249375 · Cited by 21
“Clinical data, however, show that intensive glycemic and hypertension control has limited therapeutic effectiveness for DN (Parving et al., 2012; Fried et al., 2013; Gentile et al., 2014; Hajhosseiny et al., 2014).”
BackgroundAraki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 26
“If present, an angiotensin-converting enzyme (ACE) inhibitor (which is a renin–angiotensin system (RAS) inhibitor) or angiotensin-receptor blocker (ARB) is first considered.”
BackgroundInfluentialZhang, S., Cao, M.-Q., Hou, Z., Gu, X.-Y., Chen, Y., Chen, L., Luo, Y., Chen, L.-W., Liu, D., Zhou, H.-Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.031 · Cited by 22
Brunström, M., Thomopoulos, C., Carlberg, B., Kreutz, R., & Mancia, G. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18413 · Cited by 22
Mechanisms of Disease Reversal in Focal and Segmental Glomerulosclerosis
Yang, H., & Fogo, A. B. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.04.001 · Cited by 22
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.